CSS
TBPH icon

Cubist Systematic Strategies’s Theravance Biopharma TBPH Stock Holding History

Cubist Systematic Strategies’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$195K Sell
13,341
-122,315
-90% -$1.55M ﹤0.01% 2659
2025
Q2 		$1.5M Buy
135,656
+88,684
+189% +$862K 0.01% 1718
2025
Q1 		$419K Buy
+46,972
New +$437K ﹤0.01% 2234
2024
Q2 		– Sell
-5,834
Closed -$52.3K – 3983
2024
Q1 		$52.3K Buy
+5,834
New +$54.1K ﹤0.01% 3375
2023
Q1 		– Sell
-151,440
Closed -$1.7M – 4405
2022
Q4 		$1.7M Buy
151,440
+37,573
+33% +$395K 0.01% 1986
2022
Q3 		$1.16M Buy
113,867
+23,298
+26% +$218K 0.01% 2505
2022
Q2 		$821K Sell
90,569
-63,916
-41% -$589K 0.01% 2634
2022
Q1 		$1.48M Buy
154,485
+70,663
+84% +$692K 0.01% 1730
2021
Q4 		$926K Buy
83,822
+57,738
+221% +$503K 0.01% 1972
2021
Q3 		$193K Buy
+26,084
New +$292K ﹤0.01% 2598
2021
Q1 		– Sell
-10,689
Closed -$190K – 2972
2020
Q4 		$190K Buy
+10,689
New +$192K ﹤0.01% 2258
2020
Q3 		– Sell
-30,751
Closed -$645K – 2635
2020
Q2 		$645K Buy
+30,751
New +$790K 0.01% 1448
2020
Q1 		– Sell
-27,809
Closed -$720K – 2447
2019
Q4 		$720K Buy
+27,809
New +$540K 0.01% 1361
2019
Q3 		– Sell
-28,969
Closed -$473K – 2472
2019
Q2 		$473K Buy
28,969
+15,627
+117% +$317K 0.01% 1512
2019
Q1 		$302K Buy
13,342
+5,484
+70% +$139K 0.01% 1493
2018
Q4 		$201K Buy
+7,858
New +$212K 0.01% 1539
2017
Q1 		– Sell
-931
Closed -$30K – 1856
2016
Q4 		$30K Buy
+931
New +$28.9K ﹤0.01% 1614

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cubist Systematic Strategies's TBPH Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Theravance Biopharma (TBPH) stake by 90% in Q3 2025, selling an estimated $1.55M and leaving 13,341 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #2659.

Cubist Systematic Strategies first reported a position in TBPH in Q4 2016 and has held it in 17 quarters since. The position peaked at $1.7M in Q4 2022. 162 funds tracked by Wall St. Rank hold TBPH as of Q3 2025.

  • Cubist Systematic Strategies held 13,341 shares of Theravance Biopharma worth $195K as of Q3 2025.
  • Cubist Systematic Strategies sold 122,315 Theravance Biopharma shares in Q3 2025, an estimated $1.55M.
  • Theravance Biopharma made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2659 holding.
  • Cubist Systematic Strategies first reported a position in Theravance Biopharma in Q4 2016 and has held it in 17 quarters since.
  • Cubist Systematic Strategies's Theravance Biopharma position peaked at $1.7M in Q4 2022.
  • 162 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.